FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2954403491> ?p ?o ?g. }

• W2954403491 endingPage "e16065" @default.
• W2954403491 startingPage "e16065" @default.
• W2954403491 abstract "Apatinib is an oral small-molecule tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor 2 (VEGFR-2). Some clinical trials have demonstrated that apatinib is efficacious against advanced nonsquamous NSCLC.This study aimed to probe efficacy and safety of apatinib plus docetaxel, as the second or above line treatment, in advanced nonsquamous NSCLC.Multicenter, prospective, single arm study.Three teaching hospitals centers in the Sichuan.Fourteen patients with stage IVA/B nonsquamous NSCLC had previously received at least 1 platinum-based chemotherapy regimen.Patients who were enrolled between November 2016 and January 2018 were given docetaxel (75 mg/m, i.v., d1) plus oral apatinib (250 mg/d), 4 weeks as one cycle, until disease progression or intolerance to adverse events (AE).The primary endpoint was progression-free survival (PFS). The secondary endpoints comprised objective response rate (ORR), disease control rate (DCR), overall survival (OS), and AE incidence rate.All patients carried adenocarcinoma by pathological type. The median follow-up duration was 9.76 months. Out of 14 cases, 12 were evaluable, showing ORR of 33.33%, DCR of 66.67%, DCR of 50% in cases with brain metastasis, median PFS of 2.92 months (95% CI: 1.38-4.48), and 6-month OS of 80%. Primary AEs encompassed: leukopenia in 7 cases (58.33%), hand-foot skin reaction in 5 cases (41.67%), and diarrhea in 4 cases (33.33%). Among them, grade 3 AEs were: leukopenia in 4 cases (33.33%), and hand-foot skin reaction in 1 case (8.33%). No grade 4/5 AEs were reported. Univariate and multivariate analysis were conducted respectively for PFS and OS. These factors encompassed: gender, age, gene mutations, clinical stage, ECOG scores, quantity of metastatic foci, brain metastasis, and hand-foot skin reaction. Results demonstrated zero risk factors for PFS or OS.Apatinib plus docetaxel, as the second or above line treatment, is effective and safe against advanced nonsquamous NSCLC, with good tolerance profile.NCT03416231." @default.
• W2954403491 created "2019-07-12" @default.
• W2954403491 creator A5005509338 @default.
• W2954403491 creator A5018176440 @default.
• W2954403491 creator A5036473002 @default.
• W2954403491 creator A5038471423 @default.
• W2954403491 creator A5064100733 @default.
• W2954403491 creator A5089104805 @default.
• W2954403491 date "2019-06-01" @default.
• W2954403491 modified "2023-10-14" @default.
• W2954403491 title "Efficacy and safety of apatinib plus docetaxel as the second or above line treatment in advanced nonsquamous NSCLC" @default.
• W2954403491 cites W1728628741 @default.
• W2954403491 cites W1969328947 @default.
• W2954403491 cites W1989664813 @default.
• W2954403491 cites W2055402151 @default.
• W2954403491 cites W2056163905 @default.
• W2954403491 cites W2059103130 @default.
• W2954403491 cites W2062821569 @default.
• W2954403491 cites W2075470788 @default.
• W2954403491 cites W2087598854 @default.
• W2954403491 cites W2093673524 @default.
• W2954403491 cites W2105544515 @default.
• W2954403491 cites W2105968397 @default.
• W2954403491 cites W2107304950 @default.
• W2954403491 cites W2111191667 @default.
• W2954403491 cites W2130652363 @default.
• W2954403491 cites W2136601558 @default.
• W2954403491 cites W2145092426 @default.
• W2954403491 cites W2160982674 @default.
• W2954403491 cites W2276228008 @default.
• W2954403491 cites W2601341257 @default.
• W2954403491 cites W2747382292 @default.
• W2954403491 cites W2751140959 @default.
• W2954403491 cites W2771541152 @default.
• W2954403491 cites W2772987978 @default.
• W2954403491 cites W2775429606 @default.
• W2954403491 cites W2790387499 @default.
• W2954403491 cites W2791249304 @default.
• W2954403491 cites W2792367336 @default.
• W2954403491 cites W2793587264 @default.
• W2954403491 cites W2797605742 @default.
• W2954403491 cites W2799341684 @default.
• W2954403491 cites W2801214028 @default.
• W2954403491 cites W2895471446 @default.
• W2954403491 cites W3143082516 @default.
• W2954403491 doi "https://doi.org/10.1097/md.0000000000016065" @default.
• W2954403491 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6616323" @default.
• W2954403491 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31261514" @default.
• W2954403491 hasPublicationYear "2019" @default.
• W2954403491 type Work @default.
• W2954403491 sameAs 2954403491 @default.
• W2954403491 citedByCount "9" @default.
• W2954403491 countsByYear W29544034912019 @default.
• W2954403491 countsByYear W29544034912020 @default.
• W2954403491 countsByYear W29544034912022 @default.
• W2954403491 countsByYear W29544034912023 @default.
• W2954403491 crossrefType "journal-article" @default.
• W2954403491 hasAuthorship W2954403491A5005509338 @default.
• W2954403491 hasAuthorship W2954403491A5018176440 @default.
• W2954403491 hasAuthorship W2954403491A5036473002 @default.
• W2954403491 hasAuthorship W2954403491A5038471423 @default.
• W2954403491 hasAuthorship W2954403491A5064100733 @default.
• W2954403491 hasAuthorship W2954403491A5089104805 @default.
• W2954403491 hasBestOaLocation W29544034911 @default.
• W2954403491 hasConcept C126322002 @default.
• W2954403491 hasConcept C141071460 @default.
• W2954403491 hasConcept C143998085 @default.
• W2954403491 hasConcept C203092338 @default.
• W2954403491 hasConcept C2776694085 @default.
• W2954403491 hasConcept C2780668389 @default.
• W2954403491 hasConcept C2780873365 @default.
• W2954403491 hasConcept C2781190966 @default.
• W2954403491 hasConcept C2781413609 @default.
• W2954403491 hasConcept C535046627 @default.
• W2954403491 hasConcept C71924100 @default.
• W2954403491 hasConcept C90924648 @default.
• W2954403491 hasConceptScore W2954403491C126322002 @default.
• W2954403491 hasConceptScore W2954403491C141071460 @default.
• W2954403491 hasConceptScore W2954403491C143998085 @default.
• W2954403491 hasConceptScore W2954403491C203092338 @default.
• W2954403491 hasConceptScore W2954403491C2776694085 @default.
• W2954403491 hasConceptScore W2954403491C2780668389 @default.
• W2954403491 hasConceptScore W2954403491C2780873365 @default.
• W2954403491 hasConceptScore W2954403491C2781190966 @default.
• W2954403491 hasConceptScore W2954403491C2781413609 @default.
• W2954403491 hasConceptScore W2954403491C535046627 @default.
• W2954403491 hasConceptScore W2954403491C71924100 @default.
• W2954403491 hasConceptScore W2954403491C90924648 @default.
• W2954403491 hasIssue "26" @default.
• W2954403491 hasLocation W29544034911 @default.
• W2954403491 hasLocation W29544034912 @default.
• W2954403491 hasLocation W29544034913 @default.
• W2954403491 hasLocation W29544034914 @default.
• W2954403491 hasLocation W29544034915 @default.
• W2954403491 hasOpenAccess W2954403491 @default.
• W2954403491 hasPrimaryLocation W29544034911 @default.
• W2954403491 hasRelatedWork W2167650070 @default.
• W2954403491 hasRelatedWork W2384545115 @default.

• next